Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
109.4 USD | +0.48% | +0.25% | -11.24% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-11.24% | 6.79B | C+ | ||
+27.51% | 659B | C+ | ||
+27.68% | 557B | B | ||
-4.06% | 359B | C+ | ||
+16.74% | 322B | B- | ||
+9.87% | 297B | C+ | ||
+6.30% | 215B | B+ | ||
+4.80% | 210B | B- | ||
-6.05% | 200B | A+ | ||
-8.74% | 149B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- JAZZ Stock
- Ratings Jazz Pharmaceuticals plc